Quarterly Updates14 May 2026, 05:21 pm
Akums Drugs: Monitoring Agency Report for Mar 2026
AI Summary
Akums Drugs and Pharmaceuticals Ltd. has released a Monitoring Agency Report by CRISIL Ratings Limited for the quarter ended March 31, 2026, concerning the utilization of IPO proceeds. The report, in compliance with SEBI regulations, confirms no deviations from the IPO's stated objectives. The initial IPO size was ₹6,800 million, with revised offer expenses of ₹378.21 million, resulting in net proceeds of ₹6,421.80 million. Issue expenses paid till the quarter ended March 31, 2026, amounted to ₹377.23 million.
Key Highlights
- CRISIL Ratings monitored Akums Drugs' IPO proceeds for the quarter ended March 31, 2026.
- No deviations were noted from the stated objectives of the IPO.
- The IPO's gross proceeds were ₹6,800 million, with net proceeds at ₹6,421.80 million after expenses.
- Issue expenses of ₹377.23 million were paid till March 31, 2026, with ₹0.98 million unutilized.
Price Impact
More from AKUMS